Total Payments
$78,810
2022 Payments
$117.81
Companies
13
Transactions
67
Medicare Patients
1,535
Medicare Billing
$85,890
Payment Breakdown by Category
Consulting$59,177 (75.1%)
Research$8,630 (10.9%)
Travel$7,789 (9.9%)
Other$2,232 (2.8%)
Food & Beverage$983.25 (1.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $59,177 | 24 | 75.1% |
| Unspecified | $8,630 | 6 | 10.9% |
| Travel and Lodging | $7,789 | 10 | 9.9% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $2,232 | 1 | 2.8% |
| Food and Beverage | $983.25 | 26 | 1.2% |
Payments by Type
General
$70,181
61 transactions
Research
$8,630
6 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GENZYME CORPORATION | $20,619 | 13 | $0 (2017) |
| Eisai Co., Ltd. | $17,172 | 10 | $0 (2020) |
| SANOFI-AVENTIS U.S. LLC | $9,620 | 3 | $0 (2019) |
| GlaxoSmithKline, LLC. | $8,381 | 8 | $0 (2020) |
| Novo Nordisk Inc | $5,743 | 5 | $0 (2019) |
| Eli Lilly and Company | $5,680 | 2 | $0 (2018) |
| AstraZeneca Pharmaceuticals LP | $4,855 | 9 | $0 (2019) |
| Roche Diagnostics Operations, Inc. | $4,608 | 2 | $0 (2019) |
| Bayer HealthCare Pharmaceuticals Inc. | $1,729 | 5 | $0 (2018) |
| Novo Nordisk AS | $138.04 | 6 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2022 | $117.81 | 1 | Janssen Biotech, Inc. ($117.81) |
| 2021 | $109.25 | 1 | Taiho Oncology, Inc. ($109.25) |
| 2020 | $5,725 | 3 | Eisai Co., Ltd. ($5,175) |
| 2019 | $19,865 | 18 | SANOFI-AVENTIS U.S. LLC ($9,620) |
| 2018 | $18,012 | 16 | Eisai Inc. ($5,830) |
| 2017 | $34,981 | 28 | GENZYME CORPORATION ($20,619) |
All Payment Transactions
67 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/27/2022 | Janssen Biotech, Inc. | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $117.81 | General |
| Category: Oncology | ||||||
| 10/26/2021 | Taiho Oncology, Inc. | INQOVI (Drug) | Food and Beverage | In-kind items and services | $109.25 | General |
| Category: Hematology | ||||||
| 11/23/2020 | Eisai Co., Ltd. | Lenvima (Drug) | Consulting Fee | Cash or cash equivalent | $3,125.00 | General |
| Category: Oncology | ||||||
| 10/26/2020 | Eisai Co., Ltd. | Lenvima (Drug) | Consulting Fee | Cash or cash equivalent | $2,050.00 | General |
| Category: Oncology | ||||||
| 08/26/2020 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $550.00 | General |
| 10/03/2019 | Roche Diagnostics Operations, Inc. | CD cobas Reagents (Device) | Travel and Lodging | In-kind items and services | $467.76 | General |
| Category: Centralized Diagnostics | ||||||
| 09/10/2019 | Roche Diagnostics Operations, Inc. | CD cobas Reagents (Device) | Consulting Fee | Cash or cash equivalent | $4,140.00 | General |
| Category: Centralized Diagnostics | ||||||
| 05/20/2019 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $1,950.00 | General |
| 05/20/2019 | Novo Nordisk Inc | Victoza (Drug) | — | Cash or cash equivalent | $1,950.00 | Research |
| Study: NN2211-3965 • Category: Diabetes | ||||||
| 05/13/2019 | Novo Nordisk AS | Victoza (Drug) | Travel and Lodging | In-kind items and services | $78.04 | General |
| Category: Diabetes | ||||||
| 05/13/2019 | Novo Nordisk AS | Victoza (Drug) | Food and Beverage | In-kind items and services | $26.00 | General |
| Category: Diabetes | ||||||
| 05/13/2019 | Novo Nordisk AS | Victoza (Drug) | Food and Beverage | In-kind items and services | $24.00 | General |
| Category: Diabetes | ||||||
| 05/13/2019 | Novo Nordisk AS | Victoza (Drug) | Food and Beverage | In-kind items and services | $6.00 | General |
| Category: Diabetes | ||||||
| 05/13/2019 | Novo Nordisk AS | Victoza (Drug) | Food and Beverage | In-kind items and services | $2.00 | General |
| Category: Diabetes | ||||||
| 05/13/2019 | Novo Nordisk AS | Victoza (Drug) | Food and Beverage | In-kind items and services | $2.00 | General |
| Category: Diabetes | ||||||
| 02/13/2019 | AstraZeneca Pharmaceuticals LP | BYDUREON (Drug) | Consulting Fee | Cash or cash equivalent | $500.00 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 02/13/2019 | Novo Nordisk Inc | Victoza (Drug) | — | Cash or cash equivalent | $500.00 | Research |
| Study: NN2211-3965 • Category: Diabetes | ||||||
| 01/08/2019 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $200.00 | General |
| 01/08/2019 | AstraZeneca Pharmaceuticals LP | BYDUREON (Drug) | Consulting Fee | Cash or cash equivalent | $200.00 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 01/08/2019 | Novo Nordisk Inc | Victoza (Drug) | — | Cash or cash equivalent | $200.00 | Research |
| Study: NN2211-3965 • Category: Diabetes | ||||||
| 01/07/2019 | SANOFI-AVENTIS U.S. LLC | SOTAGLIFLOZIN (Drug) | Consulting Fee | Cash or cash equivalent | $9,296.00 | General |
| 01/07/2019 | SANOFI-AVENTIS U.S. LLC | SOTAGLIFLOZIN (Drug) | Travel and Lodging | In-kind items and services | $205.18 | General |
| 01/07/2019 | SANOFI-AVENTIS U.S. LLC | SOTAGLIFLOZIN (Drug) | Food and Beverage | In-kind items and services | $118.37 | General |
| 08/07/2018 | Amgen Inc. | — | Food and Beverage | In-kind items and services | $16.17 | General |
| 06/13/2018 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $2,235.20 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| THIS ACTIVE SURVEILLANCE PROGRAM WILL MONITOR FOR ANY SIGNAL INDICATING A POSSIBLE ASSOCIATION BETWEEN TREATMENT WITH LONG-ACTING GLP-1 RAS AND THE DEVELOPMENT OF MTC IN THE UNITED STATES POPULATION | Eli Lilly and Company | $5,680 | 2 |
| NN2211-3965 | Novo Nordisk Inc | $2,650 | 3 |
| Real World Evidence Bydureon Project EQW BCB402 MTC registry | AstraZeneca Pharmaceuticals LP | $300.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 426 | 441 | $178,605 | $24,967 |
| 2022 | 3 | 374 | 403 | $156,735 | $23,235 |
| 2021 | 5 | 406 | 437 | $176,735 | $26,910 |
| 2020 | 4 | 329 | 342 | $91,970 | $10,778 |
Total Patients
1,535
Total Services
1,623
Medicare Billing
$85,890
Procedure Codes
16
All Medicare Procedures & Services
16 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 363 | 371 | $139,125 | $19,294 | 13.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 39 | 45 | $24,525 | $3,718 | 15.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 12 | 12 | $10,080 | $1,301 | 12.9% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2023 | 12 | 13 | $4,875 | $654.06 | 13.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 330 | 351 | $131,625 | $19,389 | 14.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 28 | 33 | $17,985 | $2,866 | 15.9% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2022 | 16 | 19 | $7,125 | $979.96 | 13.8% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 315 | 334 | $125,250 | $19,149 | 15.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 48 | 57 | $31,065 | $4,974 | 16.0% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 12 | 12 | $9,990 | $1,534 | 15.4% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2021 | 15 | 18 | $6,750 | $951.90 | 14.1% |
| 99212 | Established patient outpatient visit, total time 10-19 minutes | Office | 2021 | 16 | 16 | $3,680 | $300.96 | 8.2% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 155 | 166 | $58,930 | $6,497 | 11.0% |
| 99212 | Established patient office or other outpatient visit, typically 10 minutes | Office | 2020 | 113 | 114 | $24,510 | $2,625 | 10.7% |
| 99441 | Physician telephone patient service, 5-10 minutes of medical discussion | Office | 2020 | 48 | 48 | $5,030 | $1,140 | 22.7% |
| 99231 | Subsequent hospital inpatient care, typically 15 minutes per day | Facility | 2020 | 13 | 14 | $3,500 | $516.18 | 14.7% |
About Dr. Robert Tuttle, MD
Dr. Robert Tuttle, MD is a Endocrinology, Diabetes & Metabolism healthcare provider based in New York, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/01/2006. The National Provider Identifier (NPI) number assigned to this provider is 1356312854.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Robert Tuttle, MD has received a total of $78,810 in payments from pharmaceutical and medical device companies, with $117.81 received in 2022. These payments were reported across 67 transactions from 13 companies. The most common payment nature is "Consulting Fee" ($59,177).
As a Medicare-enrolled provider, Tuttle has provided services to 1,535 Medicare beneficiaries, totaling 1,623 services with total Medicare billing of $85,890. Data is available for 4 years (2020–2023), covering 16 distinct procedure/service records.
Ad
Practice Information
- Specialty Endocrinology, Diabetes & Metabolism
- Other Specialties Diabetes & Metabolism
- Location New York, NY
- Active Since 02/01/2006
- Last Updated 04/27/2009
- Taxonomy Code 207RE0101X
- Entity Type Individual
- NPI Number 1356312854
Products in Payments
- Lenvima (Drug) $17,172
- THYROGEN (Drug) $14,009
- SOTAGLIFLOZIN (Drug) $9,620
- THYROID CANCER (Drug) $6,610
- Victoza (Drug) $5,881
- TRULICITY (Drug) $5,680
- CD cobas Reagents (Device) $4,608
- BYDUREON (Drug) $4,555
- Nexavar (Drug) $600.00
- BYETTA (Drug) $300.00
- IMBRUVICA (Drug) $117.81
- INQOVI (Drug) $109.25
- Prolia (Biological) $23.08
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Endocrinology, Diabetes & Metabolism Doctors in New York
Dr. John Bilezikian, M.d, M.D
Endocrinology, Diabetes & Metabolism — Payments: $970,936
Endocrinology, Diabetes & Metabolism $970,936
Anastasios Manessis, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $719,303
Endocrinology, Diabetes & Metabolism $719,303
Stuart Weiss, M.d, M.D
Endocrinology, Diabetes & Metabolism — Payments: $520,227
Endocrinology, Diabetes & Metabolism $520,227
Dr. Brian Levy, M.d, M.D
Endocrinology, Diabetes & Metabolism — Payments: $383,360
Endocrinology, Diabetes & Metabolism $383,360
Recaredo Berbano, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $340,374
Endocrinology, Diabetes & Metabolism $340,374
Dr. Jason Baker, M.d, M.D
Endocrinology, Diabetes & Metabolism — Payments: $308,409
Endocrinology, Diabetes & Metabolism $308,409